-
公开(公告)号:US20240358799A1
公开(公告)日:2024-10-31
申请号:US18685172
申请日:2022-08-19
申请人: REPROLOGIX
发明人: Nathan Wells , Rachel Wells , Shane Morgan , Claire Timlin , Drew Crisler
CPC分类号: A61K38/24 , A61K9/0036 , A61K31/5575 , A61K31/57 , A61K38/09 , A61P15/08
摘要: Compositions and methods for the reproductive management of sheep and goats are provided. More particularly, methods for stimulating follicular maturation and/or synchronizing ovulation in sheep and goats are provided. In some embodiments, the methods and compositions described herein can be used for reproductive management of sheep and goats irrespective of their breeding season, and/or irrespective of estrus detection.
-
公开(公告)号:US12083128B2
公开(公告)日:2024-09-10
申请号:US17346440
申请日:2021-06-14
申请人: Tamara Vrabec
发明人: Tamara Vrabec
IPC分类号: A61K31/5575 , A61K45/06 , A61P9/10
CPC分类号: A61K31/5575 , A61K45/06 , A61P9/10
摘要: Provided are methods for treatment and prevention of ischemia-reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may be prescribed or undergoing anti-VEGF treatment, for example an IVAV treatment regimen, or may be diagnosed with a disorder such as sleep apnea.
-
公开(公告)号:US20240285522A1
公开(公告)日:2024-08-29
申请号:US18606551
申请日:2024-03-15
发明人: Praful Doshi , Brandon Huang , Stephen Halbe , Neil Patodia , Pavanasam Natarajan Balasubramanian
CPC分类号: A61K9/0051 , A61F9/0017 , A61K9/1075 , A61K31/46 , A61K31/5575 , A61K31/658 , A61K47/40
摘要: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having at least one coating made at least in part using printing technologies to provide drug storage and drug release structures, notably for hydrophobic drugs and that such hydrophobic drugs can be stabilized as to hydrolysis, heat, and a combination thereof. A first aspect of the present invention includes a packaged medical device that includes at least one drug delivery contact lens. A second aspect of the present invention includes a drug delivery contact lens. A third aspect of the present invention includes a method of making a drug delivery contact lens. A fourth aspect of the present invention includes an ink. A fifth aspect of the present invention includes a method of using a drug delivery contact lens to treat or prevent a disease, disorder, or condition of the eye.
-
公开(公告)号:US20240247106A1
公开(公告)日:2024-07-25
申请号:US18226713
申请日:2023-07-26
申请人: POLYACTIVA PTY LTD
发明人: Stephen Lonsdale BIRKETT , Andrew Craig DONOHUE , Asha Marina D'SOUZA , Sarah Man Yee NG , Adrian SULISTIO , Russell John TAIT , David VALADE , Alan NAYLOR , Jason WATLING , Carmen Vittoria SCULLINO
IPC分类号: C08G73/08 , A61K31/5377 , A61K31/5575 , A61K47/59
CPC分类号: C08G73/08 , A61K31/5377 , A61K31/5575 , A61K47/59
摘要: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.
-
公开(公告)号:US20240207231A1
公开(公告)日:2024-06-27
申请号:US18352807
申请日:2023-07-14
IPC分类号: A61K31/4178 , A61B5/16 , A61K31/137 , A61K31/138 , A61K31/195 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5513 , A61K31/5575 , A61P11/00
CPC分类号: A61K31/4178 , A61B5/165 , A61K31/137 , A61K31/138 , A61K31/195 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5513 , A61K31/5575 , A61P11/00 , G16H20/70
摘要: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).
-
公开(公告)号:US20240189265A1
公开(公告)日:2024-06-13
申请号:US18292097
申请日:2022-07-25
发明人: David Friend , Jennifer Kiang , Nicolas J. Pacelli , Mark Walters
IPC分类号: A61K31/196 , A61K9/00 , A61K9/06 , A61K31/5575 , A61K47/10 , A61K47/12 , A61K47/34 , A61K47/36
CPC分类号: A61K31/196 , A61K9/0034 , A61K9/06 , A61K31/5575 , A61K47/10 , A61K47/12 , A61K47/34 , A61K47/36
摘要: The present disclosure generally relates to compositions and techniques for vaginal insertion. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. The composition may also contain an active ingredient, e.g., dinoprostone, diclofenac, and/or salts thereof. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. This may, for example, allow the composition to release the active ingredient over a relatively long period of time to the vagina. In some embodiments, such compositions may be prepared by removing air from the composition to increase its viscosity or cause the composition to form a gel, etc. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
-
公开(公告)号:US11969433B2
公开(公告)日:2024-04-30
申请号:US16548531
申请日:2019-08-22
IPC分类号: A61K35/34 , A61K31/5575 , C12N5/077 , A61P9/10 , A61P21/00
CPC分类号: A61K31/5575 , A61K35/34 , C12N5/0658 , A61P9/10 , A61P21/00 , C12N2501/02 , A61K35/34 , A61K2300/00 , A61K31/5575 , A61K2300/00
摘要: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
-
公开(公告)号:US20240122943A1
公开(公告)日:2024-04-18
申请号:US18450253
申请日:2023-08-15
IPC分类号: A61K31/5575 , A61K8/69 , A61K9/00 , A61K9/06 , A61K31/165 , A61K31/191 , A61K31/216 , A61K31/25 , A61Q19/00 , A61Q19/06
CPC分类号: A61K31/5575 , A61K8/69 , A61K9/0014 , A61K9/0048 , A61K9/06 , A61K31/165 , A61K31/191 , A61K31/216 , A61K31/25 , A61Q19/005 , A61Q19/06
摘要: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V):
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7′, Z, Y, n, y, and x, are as defined herein.-
公开(公告)号:US20240115583A1
公开(公告)日:2024-04-11
申请号:US18317752
申请日:2023-05-15
IPC分类号: A61K31/5575 , A61K9/00 , A61K31/167 , A61K31/245 , A61K31/445 , A61K31/46 , A61K31/47 , A61K33/00 , A61K33/06 , A61K33/24 , A61K33/32 , A61K35/583 , A61K35/64 , A61K38/17 , A61K38/46 , A61K45/06 , A61P21/00 , A61P21/06
CPC分类号: A61K31/5575 , A61K9/0019 , A61K31/167 , A61K31/245 , A61K31/445 , A61K31/46 , A61K31/47 , A61K33/00 , A61K33/06 , A61K33/24 , A61K33/32 , A61K35/583 , A61K35/64 , A61K38/1703 , A61K38/465 , A61K45/06 , A61P21/00 , A61P21/06
摘要: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.
-
10.
公开(公告)号:US20240082262A1
公开(公告)日:2024-03-14
申请号:US18345623
申请日:2023-06-30
申请人: Allergan, Inc.
发明人: Kevin S. Warner , Kristin B. Prinn , Chetan P. Pujara , Pramod Sarpotdar , John T. Trogden , Adnan K. Salameh , Guang Wei Lu
IPC分类号: A61K31/5575 , A61K8/02 , A61K8/04 , A61K8/34 , A61K8/36 , A61K8/37 , A61K8/39 , A61K8/41 , A61K8/42 , A61K8/81 , A61K8/86 , A61K9/00 , A61K9/06 , A61K9/12 , A61K9/14 , A61K31/16 , A61K47/08 , A61K47/10 , A61K47/22 , A61P17/14 , A61Q7/00
CPC分类号: A61K31/5575 , A61K8/0216 , A61K8/022 , A61K8/042 , A61K8/046 , A61K8/34 , A61K8/342 , A61K8/345 , A61K8/361 , A61K8/37 , A61K8/375 , A61K8/39 , A61K8/41 , A61K8/42 , A61K8/8147 , A61K8/86 , A61K9/0014 , A61K9/06 , A61K9/12 , A61K9/122 , A61K9/14 , A61K31/16 , A61K47/08 , A61K47/10 , A61K47/22 , A61P17/14 , A61Q7/00 , A61K2800/592 , A61K2800/74 , A61K2800/87
摘要: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I
wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.
-
-
-
-
-
-
-
-
-